1. Home
  2. NEOV vs XBIT Comparison

NEOV vs XBIT Comparison

Compare NEOV & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeoVolta Inc.

NEOV

NeoVolta Inc.

HOLD

Current Price

$3.88

Market Cap

97.7M

Sector

Miscellaneous

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.17

Market Cap

70.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEOV
XBIT
Founded
2018
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Pharmaceuticals and Biotechnology
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.7M
70.1M
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
NEOV
XBIT
Price
$3.88
$2.17
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.8M
47.0K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,426,835.00
N/A
Revenue This Year
$150.56
N/A
Revenue Next Year
$5.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
218.59
N/A
52 Week Low
$1.36
$2.09
52 Week High
$7.13
$3.44

Technical Indicators

Market Signals
Indicator
NEOV
XBIT
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NEOV
XBIT

About NEOV NeoVolta Inc.

NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: